785,739 Shares in Hims & Hers Health, Inc. $HIMS Bought by Bienville Capital Management LLC

Bienville Capital Management LLC bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, Holdings Channel reports. The fund bought 785,739 shares of the company’s stock, valued at approximately $27,242,000. Hims & Hers Health accounts for 3.6% of Bienville Capital Management LLC’s holdings, making the stock its 9th largest position.

Other hedge funds also recently added to or reduced their stakes in the company. Versant Capital Management Inc grew its position in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after purchasing an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares during the period. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health in the third quarter worth about $28,000. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter worth about $30,000. Finally, Greenline Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $36,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. UBS Group set a $23.00 price target on Hims & Hers Health in a research report on Friday, May 22nd. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $32.50.

Insider Transactions at Hims & Hers Health

In related news, insider Deborah Autor sold 16,773 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total value of $467,128.05. Following the completion of the sale, the insider owned 48,961 shares of the company’s stock, valued at approximately $1,363,563.85. The trade was a 25.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Carroll sold 23,726 shares of the company’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider owned 181,861 shares of the company’s stock, valued at $6,365,135. This represents a 11.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 190,227 shares of company stock worth $6,133,613 in the last ninety days. Company insiders own 11.76% of the company’s stock.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Negative Sentiment: A securities class action has been filed on behalf of investors who purchased HIMS securities between August 4, 2025, and July 29, 2026. The lawsuit alleges that the company and certain executives violated federal securities laws by making misleading statements or omitting material information related to the FTC’s allegations. Investors have until November 2, 2026, to seek lead-plaintiff status. Kaplan Fox class action announcement
• Negative Sentiment: A wave of investor-rights firms, including Robbins LLP, Bronstein Gewirtz & Grossman, and Glancy Prongay Wolke & Rotter, is urging investors with losses to participate in the case. Although these announcements largely repeat the same lawsuit details, the concentrated legal attention reinforces concerns about possible damages, defense expenses, and management distraction. Robbins LLP class action reminder
• Negative Sentiment: One legal notice linked the lawsuit to an over-14% stock decline and allegations involving privacy and billing practices. The claims have not been proven, but they add headline risk while the FTC matter proceeds. Kahn Swick & Foti legal notice
• Neutral Sentiment: Recent earnings also remain a backdrop: Hims & Hers reported revenue growth of 38.2% year over year and exceeded revenue expectations, but its quarterly EPS loss was substantially wider than analysts expected. This mixed operating performance may limit investor support amid the legal uncertainty. Zacks earnings review

Hims & Hers Health Stock Performance

NYSE HIMS opened at $27.81 on Thursday. The stock has a market capitalization of $6.49 billion, a price-to-earnings ratio of -44.14 and a beta of 2.42. The stock has a 50-day moving average of $31.23 and a 200 day moving average of $27.07. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm’s quarterly revenue was up 38.2% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 earnings per share.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.